Surgical infections · 2010
Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zilberberg Marya D, Mody Samir H, Chen Joyce, Shorr Andrew F
Аннотация
BACKGROUND: Ventilator-associated pneumonia (VAP) is a common complication of critical illness among surgical and trauma patients. Inappropriate empiric treatment of VAP increases the mortality rate. The rates of Pseudomonas aeruginosa (PA) VAP susceptibility to doripenem (DOR) are higher than those to imipenem-cilastatin (IMI). We developed a model to quantify outcome differences between strategies of empiric treatment of VAP with DOR vs. IMI.
METHODS: We designed a cost-effectiveness model comparing empiric treatment of VAP with DOR vs. IMI from both the hospital and societal perspectives. We examined the differences in the number of deaths, hospital length of stay (LOS), total costs, and quality-adjusted life years (QALY) under each scenario and conducted Monte Carlo simulations and sensitivity analyses to determine the stability of our estimates. Drug costs were taken as 80% of wholesale acquisition costs, with other inputs derived from the literature.
RESULTS: In the base case analysis, assuming a PA-VAP attributable mortality rate of 38.4% and a 49% relative risk reduction in deaths in PA-sensitive (PA-S) infections to empiric drug compared with a resistant PA (PA-R) organism, DOR use resulted in three additional deaths avoided, 117.4 days of hospitalization averted, and hospital savings of $422,524 per 1,000 patients treated at a cost of $5,748/QALY. All estimates were most sensitive to the costs of treating PA-S and PA-R infections. In a multivariable analysis, hospital cost savings persisted across >80% of the simulations (95% confidence interval $432,615-$2,148,540).
CONCLUSIONS: Given the current microbiologic sensitivity profile of PA to DOR and IMI, and depending on the local susceptibility patterns and in institutions where DOR in vitro susceptibilities are superior to those of other carbapenems for PA clinical isolates, empiric treatment of VAP with DOR may dominate that with IMI by being both life- and cost-saving.
METHODS: We designed a cost-effectiveness model comparing empiric treatment of VAP with DOR vs. IMI from both the hospital and societal perspectives. We examined the differences in the number of deaths, hospital length of stay (LOS), total costs, and quality-adjusted life years (QALY) under each scenario and conducted Monte Carlo simulations and sensitivity analyses to determine the stability of our estimates. Drug costs were taken as 80% of wholesale acquisition costs, with other inputs derived from the literature.
RESULTS: In the base case analysis, assuming a PA-VAP attributable mortality rate of 38.4% and a 49% relative risk reduction in deaths in PA-sensitive (PA-S) infections to empiric drug compared with a resistant PA (PA-R) organism, DOR use resulted in three additional deaths avoided, 117.4 days of hospitalization averted, and hospital savings of $422,524 per 1,000 patients treated at a cost of $5,748/QALY. All estimates were most sensitive to the costs of treating PA-S and PA-R infections. In a multivariable analysis, hospital cost savings persisted across >80% of the simulations (95% confidence interval $432,615-$2,148,540).
CONCLUSIONS: Given the current microbiologic sensitivity profile of PA to DOR and IMI, and depending on the local susceptibility patterns and in institutions where DOR in vitro susceptibilities are superior to those of other carbapenems for PA clinical isolates, empiric treatment of VAP with DOR may dominate that with IMI by being both life- and cost-saving.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsCarbapenemsCilastatinCilastatin, Imipenem Drug CombinationCost-Benefit AnalysisDoripenemDrug CombinationsHumansImipenemLength of StayMiddle AgedPneumonia, Ventilator-AssociatedPseudomonas InfectionsPseudomonas aeruginosaQuality-Adjusted Life YearsYoung Adult